Tenax Therapeutics
TENX
NASDAQ
IPO1995
about TENX
Tenax Therapeutics focuses on developing innovative treatments for respiratory diseases, including chronic obstructive pulmonary disease (COPD), with its lead product TD-4249 targeting the reduction of mucus production by inhibiting a key biomarker.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $12.00 | $14.60 | $12.00 | $68.80M | 2.13M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.40 | n/a | n/a | 0% | 0% | 0% |